New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
13:00 EDTYRCW, TGT, SHLD, ICPT, SWS, HTH, CHTPOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday after a report showed that U.S. hiring slowed markedly in December. The averages began the session in positive territory, as a "bad news is good news" attitude appeared to breifly return to the market, but the market never gained upside momentum. The averages crossed into negative territory before the end of the first hour of trading and have drifted in negative ground since then. ECONOMIC EVENTS: In the U.S., employers added 74K jobs in December, which was the smallest jobs gain since January 2011 and fell well short of expectations for 200K jobs to have been added. The unemployment rate unexpectedly fell to 6.7% from 7% in November, but the drop occurred largely because more people stopped looking for work. In China, the nation's trade surplus of $25.6B for December was below the $32.2B surplus expected. Export growth of 4.3% was slower than the prior month and missed expectations, while imports rose by 8.3%, which was more than expected. In Europe, S&P reaffirmed at its AAA rating on Germany with a stable outlook. COMPANY NEWS: Target (TGT) shares slipped 1% after the company increased its estimate of people affected by its recent security breach to 70 million and said additional information may have been stolen. The company also cut its forecast for the fourth quarter performance of its U.S. unit, noting that it now expects same-store sales will fall about 2.5%, compared with a prior view that they would be flat compared to last year. Target stated that its new expectation reflects stronger-than-expected Q4 sales prior to the company’s announcement of its data breach and "meaningfully weaker-than expected" sales since the announcement... Another department store owner, Sears Holdings (SHLD), plunged 12% after forecasting worse than expected fourth quarter losses and saying domestic comparable store sales for the quarter-to-date fell 5.7% at Kmart and 9.2% at Sears stores in the U.S. MAJOR MOVERS: Among the notable gainers was Intercept Pharmaceuticals (ICPT), which rose another 70% after its stock nearly tripled yesterday following the company's trial of obeticholic acid for the treatment of non-alcoholic steatohepatitis being stopped early for efficacy. Also higher was SWS Group (SWS), which rose about 21% to $7.33 near midday after Hilltop Holdings (HTH) offered to buy the rest of SWS that it doesn't already own for $7 a share in cash and Hilltop stock. Hilltop shares also rose nearly 9% after making the proposal. Among the noteworthy losers was Chelsea Therapeutics (CHTP), which fell 29% after the FDA posted briefing documents related to a review of a resubmission for the company's Northera drug. Also lower were shares of trucker YRC Worldwide (YRCW), which declined 13% after members of the International Brotherhood of Teamsters did not approve the memorandum of understanding extension proposal made by the company. INDEXES: Near 1 pm ET, the Dow was down 35.43, or 0.22%, to 16,409.33, the Nasdaq was down 1.71, or 0.04%, to 4,154.49, and the S&P 500 was down 1.10, or 0.06%, to 1,837.03.
News For TGT;SHLD;ICPT;SWS;HTH;CHTP;YRCW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 9, 2014
09:41 EDTTGTBofA/Merrill retail analysts hold an analyst/industry conference call
Subscribe for More Information
09:03 EDTICPTIntercept pullback a buying opportunity, says Summer Street
Subscribe for More Information
08:01 EDTTGTTarget CEO hands-on with Canadian turnaround, Globe and Mail says
Brian Cornell, the new CEO of Target, told The Globe and Mail in an interview that he is taking a hands-on approach to repairing the company’s Canadian business and that he will travel north on a “regular” basis to oversee the turnaround. Reference Link
05:45 EDTSHLDStocks with implied volatility movement; WLT SHLD
Stocks with implied volatility movement; Walter Energy (WLT) 159, Sears (SHLD) 108 according to iVolatility.
October 8, 2014
13:43 EDTSHLDDepartment stores fall after J.C. Penney cuts view due to difficult environment
Subscribe for More Information
12:42 EDTICPTIntercept weakness a buying opportunity, says Wedbush
Subscribe for More Information
12:40 EDTSHLDSears says meeting obligations, has 'ample inventory and liquidity'
Subscribe for More Information
12:36 EDTSHLDSears calls recently published article 'misleading'
Subscribe for More Information
12:35 EDTSHLDSears says 'has financial flexibility' and is 'meeting its obligations'
12:25 EDTSHLDOn The Fly: Midday Wrap
Subscribe for More Information
12:11 EDTICPTIntercept management to meet with Oppenheimer
Subscribe for More Information
10:38 EDTSHLDHigh option volume stocks
High option volume stocks: FRAN RMTI ACM CY CLNY SMH BEAV SIG CTB DUG SHLD
10:24 EDTSHLDSears vendor to withhold products, Bloomberg reports
Subscribe for More Information
10:23 EDTSHLDSears Holdings volatility spikes after Bloomberg says vendor to halt shipments
Sears Holdings October weekly call option implied volatility is at 200 above a level of 100 from the open, October is at 127, November is at 88, December is at 78, March is at 68; compared to its 26-week average of 54 according to Track Data, suggesting large near term price movement after Bloomberg says vendor to halt shipments.
10:11 EDTSHLDSears drops 9% after Bloomberg says vendor to halt shipments
Subscribe for More Information
09:20 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
07:05 EDTICPTIntercept says FLINT trial NASH data will not be presented at AASLD
Intercept Pharmaceuticals announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases, or AASLD, Annual Meeting, being held in Boston, Massachusetts from November 7-11. Obeticholic acid, or OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor in development for primary biliary cirrhosis, nonalcoholic steatohepatitis, primary sclerosing cholangitis and other chronic liver and intestinal diseases. CEO Mark Pruzanski said, "We are pleased that several key abstracts from Intercept's Phase 3 program for OCA in PBC will be presented at AASLD. With respect to the NIDDK-sponsored FLINT trial of OCA in NASH, we have learned that the NASH CRN has decided to focus on finalizing the manuscript intended for near term publication in lieu of presentation at AASLD. We are reaffirming the previously reported top-line results based on a revised draft manuscript that our partners at NIDDK have provided us. We believe that peer reviewed publication of the FLINT data will mark another important milestone supportive of OCA's potential as a novel therapy for patients with NASH and associated liver fibrosis. In the meantime, we continue preparing for the initiation of our Phase 3 NASH program in the first half of 2015."
06:16 EDTSHLDSears Holdings volatility elevated
Subscribe for More Information
October 7, 2014
10:02 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:32 EDTICPTIntercept initiated with an Outperform at JMP Securities
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use